Report Sections

See All Reports

  • HP:0012532: Chronic pain
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0012532: Chronic pain

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (23)


    Name (Synonyms) Correlation
    drug808 Colchicine Wiki 0.36
    drug3568 VCPM Wiki 0.33
    drug811 Colchicine Pill Wiki 0.33
    Name (Synonyms) Correlation
    drug376 BIO101 Wiki 0.33
    drug810 Colchicine 1 MG Oral Tablet Wiki 0.33
    drug3166 Standard COVID-19 care Wiki 0.33
    drug2628 Prednisone tablet Wiki 0.33
    drug640 COVID-19 test Wiki 0.33
    drug697 Cannabis, Medical Wiki 0.33
    drug3031 Self-Compassion for Chronic Pain Virtual Group Treatment Program Wiki 0.33
    drug1230 Exercise Group Wiki 0.33
    drug3330 Tele-Yoga Therapy Wiki 0.33
    drug1183 Emtricitabine/tenofovir Wiki 0.33
    drug3214 Standard therapy for COVID-19 according to the stablished hospital protocols. Wiki 0.33
    drug1703 Intervention program Wiki 0.33
    drug2886 Rosuvastatin Wiki 0.33
    drug4039 questionnaire assesment Wiki 0.30
    drug1985 Meditation (1 x 20-minute guided audio training) Wiki 0.24
    drug4087 standard of care Wiki 0.19
    drug812 Colchicine Tablets Wiki 0.17
    drug3219 Standard treatment Wiki 0.13
    drug491 Blood sampling Wiki 0.12
    drug2490 Placebo Wiki 0.03

    Correlated MeSH Terms (32)


    Name (Synonyms) Correlation
    D059350 Chronic Pain NIH 1.00
    D000070627 Chronic Traumatic Encephalopathy NIH 0.33
    D010148 Pain, Intractable NIH 0.33
    Name (Synonyms) Correlation
    D005879 Tourette Syndrome NIH 0.33
    D003424 Crohn Disease NIH 0.33
    D000070642 Brain Injuries, Traumatic NIH 0.24
    D000690 Amyotrophic Lateral Sclerosis NIH 0.24
    D012640 Seizures NIH 0.24
    D016472 Motor Neuron Disease NIH 0.24
    D006526 Hepatitis C NIH 0.24
    D001714 Bipolar Disorder NIH 0.19
    D005356 Fibromyalgia NIH 0.17
    D000755 Anemia, Sickle Cell NIH 0.17
    D001930 Brain Injuries, NIH 0.15
    D001927 Brain Diseases NIH 0.15
    D010300 Parkinsonian NIH 0.14
    D015212 Inflammatory Bowel Diseases NIH 0.13
    D012598 Scoliosi NIH 0.12
    D009103 Multiple Sclerosis NIH 0.12
    D003095 Collagen Diseases NIH 0.11
    D001172 Arthritis, Rheumatoid NIH 0.10
    D012216 Rheumatic Diseases NIH 0.10
    D001168 Arthritis NIH 0.09
    D040921 Stress Disorders, Traumatic NIH 0.07
    D004194 Disease NIH 0.07
    D013577 Syndrome NIH 0.07
    D013313 Stress Disorders, Post-Traumatic NIH 0.06
    D014947 Wounds and Injuries NIH 0.06
    D003141 Communicable Diseases NIH 0.02
    D007239 Infection NIH 0.02
    D045169 Severe Acute Respiratory Syndrome NIH 0.01
    D018352 Coronavirus Infections NIH 0.01

    Correlated HPO Terms (9)


    Name (Synonyms) Correlation
    HP:0100280 Crohn's disease HPO 0.33
    HP:0006802 Abnormal anterior horn cell morphology HPO 0.24
    HP:0100754 Mania HPO 0.24
    Name (Synonyms) Correlation
    HP:0007354 Amyotrophic lateral sclerosis HPO 0.24
    HP:0001250 Seizure HPO 0.19
    HP:0001298 Encephalopathy HPO 0.15
    HP:0002037 Inflammation of the large intestine HPO 0.13
    HP:0001370 Rheumatoid arthritis HPO 0.11
    HP:0001369 Arthritis HPO 0.09

    Clinical Trials

    Navigate: Correlations   HPO

    There are 9 clinical trials


    1 Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19

    This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.

    NCT03944447
    Conditions
    1. Chronic Pain
    2. Chronic Pain Syndrome
    3. Chronic Pain Due to Injury
    4. Chronic Pain Due to Trauma
    5. Fibromyalgia
    6. Seizures
    7. Hepatitis C
    8. Cancer
    9. Crohn Disease
    10. HIV/AIDS
    11. Multiple Sclerosis
    12. Traumatic Brain Injury
    13. Sickle Cell Disease
    14. Post Traumatic Stress Disorder
    15. Tourette Syndrome
    16. Ulcerative Colitis
    17. Glaucoma
    18. Epilepsy
    19. Inflammatory Bowel Diseases
    20. Parkinson Disease
    21. Amyotrophic Lateral Sclerosis
    22. Chronic Traumatic Encephalopathy
    23. Anxiety
    24. Depression
    25. Insomnia
    26. Autism
    27. Opioid-use Disorder
    28. Bipolar Disorder
    29. Covid19
    30. SARS-CoV Infection
    31. COVID-19
    32. Corona Virus Infection
    33. Coronavirus
    Interventions
    1. Drug: Cannabis, Medical
    MeSH:Infection Communicable Diseases Hepatitis C Coronavirus Infections Severe Acute Respiratory Syndrome Fibromyalgia Crohn Disease Inflammatory Bowel Diseases Parkin Parkinson Disease Multiple Sclerosis Brain Injuries Brain Injuries, Traumatic Seizures Motor Neuron Disease Amyotrophic Lateral Sclerosis Brain Diseases Tourette Syndrome Chronic Traumatic Encephalopathy Anemia, Sickle Cell Disease Syndrome Sclerosis Chronic Pain Wounds and Injuries Stress Disorders, Traumatic Bipolar Disorder Stress Disorders, Post-Traumatic
    HPO:Abnormal anterior horn cell morphology Amyotrophic lateral sclerosis Bilateral tonic-clonic seizure Bipolar affective disorder Chronic pain Crohn's disease Encephalopathy Focal-onset seizure Generalized-onset seizure Inflammation of the large intestine Mania Seizure

    Primary Outcomes

    Description: Covid-19 infection rates in cannabis users will be compared to rates in the general population. Our online questionnaire responses will compare infection rates of cannabis users in this study against the Johns Hopkins University Coronavirus Research Center data (https://coronavirus.jhu.edu).

    Measure: Prevention of COVID-19

    Time: Five years

    Description: Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population. Patients will answer the widely used FLU-PRO questionnaire, which asks about flu symptoms and severity, to capture diagnoses, symptoms, and medical interventions related to COVID-19. The data from cannabis user patients will be compared with national and international data surveys, such as the Covid Symptom Study (https://covid.joinzoe.com/us-2).

    Measure: Treatment of COVID-19

    Time: Five years

    Description: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.

    Measure: Treatment of Symptoms

    Time: Five years

    Secondary Outcomes

    Description: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.

    Measure: Cannabis Impact on Quality of Life

    Time: Five years

    Description: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.

    Measure: Cannabis Route and Dosing

    Time: Five years

    Description: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.

    Measure: Monitoring Adverse Events

    Time: Five years
    2 Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak

    Clinical data about psychological impact of quarantine are well studied in transient event or more prolonged situation like jail incarceration. In recent metaanalysis, psychological impact of quarantine was well documented in a specific population during first SARS epidemy. Even after the end of quarantine several patients were still with symptom of avoiding mainly agoraphobia, frequent hand washing and a carefull return to normal life COVID-19 infection is already associated with psychological symptom like anxiety, depression, sleep disorders and symptoms of acute stress However psychological impact of quarantine is on none in chronic painful inflammatory rheumatism in France. The prevalence of rheumatoid arthritis is 0.5% of the population with frequent comorbidity such as anxiety and depression. During the quarantine secondary to COVID-19 pandemic it's possible to evaluated the psychological impact of adult RA patients. The present study is an "emergency" being realize before the end of the quarantine.

    NCT04351399
    Conditions
    1. Sars-CoV2
    2. Rheumatic Diseases
    3. Rheumatoid Arthritis
    4. Chronic Pain
    Interventions
    1. Other: questionnaire assesment
    MeSH:Arthritis Arthritis, Rheumatoid Rheumatic Diseases Collagen Diseases Chronic Pain
    HPO:Arthritis Chronic pain Polyarticular arthritis Rheumatoid arthritis

    Primary Outcomes

    Measure: Frequency of RA patients with emotional impact (feeling of isolation)

    Time: maximum 1 week from baseline on

    Secondary Outcomes

    Description: Self reported questionnaire with questions to assess the characteristic,intensity of pain on quality of life, and consumption of analgesic.

    Measure: self-reported questionnaire for painful

    Time: maximum 1 week from baseline on
    3 Psychological Impact of Quarantine in Chronic Pain Patient During COVID-19 Outbreak

    In the context of quarantine with COVID-19, we will study the experience and psychological impact of pain in adult patients living with chronic pain. We will evaluate the link between the question of physical and psychological confinement in the experience of pain in this particular situation

    NCT04353011
    Conditions
    1. Sars-CoV2
    2. Chronic Pain
    Interventions
    1. Other: questionnaire assesment
    MeSH:Chronic Pain
    HPO:Chronic pain

    Primary Outcomes

    Measure: Hospital Anxiety and Depression Scale questionnaire

    Time: 1 week from baseline on

    Secondary Outcomes

    Measure: Quality of life (SF36)

    Time: 1 week from baseline on

    Measure: self-reported questionnaire for painful

    Time: 1 week from baseline on

    Measure: qualitive questionnaire

    Time: 1 week from baseline on
    4 The Impact of Quarantine and the Effectiveness of Telerehabilitation in Patients With Chronic Pain During COVID-19 Pandemic.

    The quarantine during COVID-19 pandemic has changed daily routine. Staying at home for prolonged periods of time can pose a significant challenge for patients with chronic pain. The purpose of the current study is to investigate how the quarantine effects of psychosocial factors, quality of life, sleep, nutrition and physical activity in patients with chronic musculoskeletal pain. Another purpose is to examine whether a telerehabilitation exercise program is effective during the lockdown period.

    NCT04381000
    Conditions
    1. Chronic Pain
    Interventions
    1. Other: Exercise Group
    MeSH:Chronic Pain
    HPO:Chronic pain

    Primary Outcomes

    Description: To measure the levels of anxiety and depression Hospital Anxiety and Depression Scale (HADS), will be used. Patients have to score 14 opinions. Seven of the items relate to anxiety and seven relate to depression. A cut-off point of 8/21 for anxiety or depression has been recommended.

    Measure: Anxiety and Depression

    Time: Change From Baseline in HADS at 40 days

    Description: To measure quality of life, EQ-5D-3L will be used. The EQ-5D-3L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results into a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

    Measure: Quality of Life and overall health

    Time: Change From Baseline in EQ-5D-3L at 40 days

    Description: The Numeric Pain Rating Scale (NPRS) is a unidimensional measure of pain intensity in adults and it will be used in the current study. The most commonly used is the 11-item NPRS. The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable").The NPRS is a valid and reliable scale to measure pain intensity. In this study, will rate current pain intensity and mean pain intensity during the past 7 days.

    Measure: Pain Intensity

    Time: Change From Baseline in NPRS Scores at 40 days

    Secondary Outcomes

    Description: The Pittsburgh Sleep Quality Index (PSQI) is an effective instrument used to measure the quality and patterns of sleep in the older adult. PSQI will be used to assess quality and patterns of sleep in the current study. PSQI differentiates "poor" from "good" sleep by measuring seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction over the last month. The client self-rates each of these seven areas of sleep. Scoring of the answers is based on a 0 to 3 scale, whereby 3 reflects the negative extreme on the Likert Scale. A global sum of "5" or greater indicates a "poor" sleeper. Although there are several questions that request the evaluation of the client's bed mate or roommate, these are not scored, nor reflected in the attached instrument. An update to the scoring: if 5 is not complete or the value is missing, it now counts as a "0".

    Measure: Quality and patterns of sleep

    Time: Change From Baseline in PSQI Scores at 40 days

    Description: Patients' illness perceptions will be measured based on the Brief Illness Perception Questionnaire (BIPQ). The patient has to rate 8 statements on a 10-point scale (1-10). The higher the score, the greater is the extent to which the patient's illness perceptions are threatening him or her.

    Measure: Patients' illness perceptions

    Time: Change From Baseline in BIPQ Scores at 40 days

    Description: Disability will be assessed using Oswestry Disability Index (ODI) that present ten sections cover Pain, Personal Care, Lifting, Walking, Sitting, Standing, Sleeping, Sex Life, Social Life, and Traveling. Each section has six statements reflecting an increasing level of disability. Respondents choose the statement that most applies to them in each section. The first statement is scored 0; the second is scored 1 and so on to 5 for the last statement. The sum of the section scores is divided by 50 if all sections are completed and multiplied by 100 for the final percentage score.

    Measure: Disability

    Time: Change From Baseline in ODI Scores at 40 days
    5 Early Care, Therapeutic Education, and Psychological Intervention for the Management of Post-intensive Care Syndrome and Chronic Pain After Coronavirus Disease 2019 Infection. Simple-blind, Controlled, Randomized Trial.

    COVID-19 (coronavirus 2019) disease has led to a large number of hospital admissions, many of which require admission to intensive care (ICU). Post-intensive care syndrome (PICS) is defined as deterioration or worsening of previous deterioration in the mental, physical or cognitive status that appears as a consequence of a critical illness and which persists after acute hospital care. Also, there is evidence that patients who survive a critical illness have a high prevalence of moderate to extreme chronic pain. Patients with COVID-19 disease are an especially susceptible population to develop PICS due to acute respiratory distress syndrome (ARDS) survivors have significant long-term deterioration in mental, cognitive, and functional health. This study hypothesis is that a specific care program based on early therapeutic education and psychological intervention improves the quality of life of patients at risk of developing PICS and chronic pain after COVID-19 disease.

    NCT04394169
    Conditions
    1. Post ICU Syndrome
    2. Chronic Pain
    3. Covid-19
    Interventions
    1. Behavioral: Intervention program
    MeSH:Syndrome Chronic Pain
    HPO:Chronic pain

    Primary Outcomes

    Description: Health-related quality of life reported by the patient assessed through the visual analogue scale of the EQoL 5D/5L questionnaire at six months after discharge. [European quality of life 5 dimensions/5 levels ; from 0 (the worst imaginable health) to 100 (the best imaginable health) ]

    Measure: Impact of intervention program on health-related quality of life (VAS)

    Time: Six months after discharge

    Secondary Outcomes

    Description: Health-related quality of life reported by the patient assessed through the visual analogue scale of the EQoL 5D / 5L questionnaire at three months after discharge. [European quality of life 5 dimensions/5 levels ; from 0 (the worst imaginable health) to 100 (the best imaginable health)]

    Measure: Impact of intervention program on health-related quality of life (VAS)

    Time: Three months after discharge.

    Description: Health-related quality of life reported by the patient assessed through health index of the EQoL 5D/5L questionnaire at three months after discharge. [European quality of life 5 dimensions/5 levels ; the questionnaire assesses quality of life in study participants according to 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each scored according to a scale of 1 (no problems) to 5 (indicating extreme problems) and generating a 5-digit code corresponding to quality of life]

    Measure: Impact of intervention program on health-related quality of life (Index)

    Time: Three months after discharge

    Description: Health-related quality of life reported by the patient assessed through health index of the EQoL 5D/5L questionnaire at six months after discharge. [European quality of life 5 dimensions/5 levels ; the questionnaire assesses quality of life in study participants according to 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each scored according to a scale of 1 (no problems) to 5 (indicating extreme problems) and generating a 5-digit code corresponding to quality of life]

    Measure: Impact of intervention program on health-related quality of life (Index)

    Time: Six months after discharge

    Description: Chronic pain intensity defined by BPI questionnaire (short version), at three and six months after discharge. [Brief pain inventory; A multidimensional questionnaire that evaluates pain intensity in the last 24 hours (worst, lowest, average) and current (right now). The questions are rated on a scale of 0 to 10, with 10 being the worst possible value. Subsequently, the average intensity score (BPI intensity score) is calculated.]

    Measure: Impact of intervention program on chronic pain (intensity)

    Time: Three and six months after discharge.

    Description: Limitation of daily activities due to chronic pain, defined by BPI (short version), at three and six months after discharge. [Brief pain inventory; Multidimensional questionnaire that assesses the impact of pain on daily activities (general activity, encouragement, work, relationships with other people, sleep, enjoying life and the ability to walk). The questions are rated on a scale of 0 to 10, with 10 being the worst possible value. Subsequently, the mean score of the responses related to pain interference in activities (BPI interference score) is calculated.]

    Measure: Impact of intervention program on chronic pain (limitation of daily activities)

    Time: Three and six months after discharge.

    Description: Pain catastrophization assessed by Pain Catastrophizing Scale at three and six months after hospital discharge. [Pain Catastrophizing Scale; Consisting of 13 questions that explore the frequency of thoughts and feelings that the interviewees have in the presence of current or anticipated pain, which are grouped into three scoring subscales (magnification, rumination and defenselessness). Each question is rated on a 5-point scale (0: not at all; 4: all the time). Being the maximum total score of 52 points.]

    Measure: Impact of intervention program on chronic pain (Pain catastrophization)

    Time: Three and six months after discharge.

    Description: Clinically significant anxiety or depression symptoms prevalence at three and six months, assessed by the HAD test. [hospital anxiety and depression test; 14 questions, with two subscales, one for anxiety and the other for depression, with seven items each, the maximum score is 21 for each subscale. The cut-off points from zero to seven imply the absence of clinically relevant anxiety and depression, from eight to ten symptoms that require consideration and from 11 to 21 reports the presence of relevant symptoms, with a very probable diagnosis of anxiety or depression.]

    Measure: Impact of intervention program on anxiety or depression incidence

    Time: Three and six months after discharge.

    Description: Probable post-traumatic stress syndrome prevalence at three and six months after discharge assessed by the DSM ( Diagnostic and Statistical Manual of Mental Disorders) V PTSD Checklist questionnaire (PCL-5) [PTSD Checklist questionnaire; It contains 20 questions that correspond to the DSM V PTSD (Post Traumatic Stress Disorder) criteria. Participants rated their symptoms on a scale of 0 (not at all), 1 (slightly), 2 (moderately), 3 (quite) to 4 (extremely), with a score ranging from 0 to 80. A total of the severity of the symptoms can be made, adding the score of each question (interval 0-80). The severity of each symptom can be evaluated, adding the score of the questions. The cut-off point to use for a provisional diagnosis of PTSD is 31 points.]

    Measure: Impact of intervention on probable post-traumatic stress syndrome incidence

    Time: Three and six months after discharge.
    6 A Self-compassion Group-based Treatment for Chronic Pain Via Video Conferencing During the COVID-19 Pandemic: Feasibility Study for a Potential New Mode of Treatment Delivery

    As a result of COVID-19 and measures taken by the Canadian Government to reduce the transmission of the virus, in-person psychology services have been suspended. Psychology services are now being conducted via video conferencing. The purpose of the current project is to pilot-test a 6-week Self Compassion Treatment for Chronic Pain delivered virtually, in order to understand its utility in the current environment. The treatment is to be delivered through a secure professional ZOOM licence. Objective 1 of the project is to assess the feasibility and acceptability of attending the treatment group through virtual participation. Objective 2 is to assess the effectiveness of the group treatment in improving self-compassion, mental health, relationship with pain, and quality of life.

    NCT04413006
    Conditions
    1. Chronic Pain
    Interventions
    1. Behavioral: Self-Compassion for Chronic Pain Virtual Group Treatment Program
    MeSH:Chronic Pain
    HPO:Chronic pain

    Primary Outcomes

    Description: Change over time in scores on the Self-Compassion Scale (SCS) (score range is 12-60 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

    Measure: Change over time in Scores on the Self-Compassion Scale (SCS)

    Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

    Description: Change over time in scores on the Pain Disability Index (score range is 0-70 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

    Measure: Change over time in Scores on the Pain Disability Index

    Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

    Secondary Outcomes

    Description: Change over time in scores on the on the Chronic Pain Acceptance Questionnaire - 8 (CPAQ-8) (score range is 0-48 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

    Measure: Change over time in Scores on the Chronic Pain Acceptance Questionnaire - 8

    Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

    Description: Change over time in scores on the on the Pain Catastrophizing Scale-6 (PCS-6) (score range is 0-24 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

    Measure: Change over time in Scores on the Pain Catastrophizing Scale -6

    Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

    Description: Change over time in Scores on the Pain Self-Efficacy Questionnaire-4 (PSEQ-4) (score range is 0-24 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

    Measure: Change over time in Scores on the Pain Self-Efficacy Questionnaire-4

    Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

    Description: Change over time in scores on the Numeric Rating Scale (NRS) for pain (score range is 0-10 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

    Measure: Change over time in Pain Intensity

    Time: at treatment end (6-weeks after beginning treatment) and 3 months later

    Description: Change over time in scores on the Patient Health Questionnaire-9 (PHQ-9) (score range is 0-27 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

    Measure: Change over time in Depression Symptoms as measured by the Patient Health Questionnaire-9 (PHQ-9)

    Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

    Description: Change over time in scores on the Generalized Anxiety Scale (GAD-7) (score range is 0-21 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

    Measure: Changes over time in Anxiety Symptoms as measured by the Generalized Anxiety Scale-7

    Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

    Description: Change over time in scores on the Physical Health and Mental Health Quality of Life scores from the PROMIS GLOBAL-10 (score range is 7-35 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

    Measure: Change over time in Quality of Life as measured by the PROMIS GLOBAL- 10

    Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

    Description: Changes over time in score on the Mindfulness Attention and Awareness Scale (MAAS) (score range is 15-90 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

    Measure: Changes over time in Mindfulness

    Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

    Other Outcomes

    Description: Scores on the Client Satisfaction Questionnaire

    Measure: Client Satisfaction

    Time: post treatment (6 weeks after beginning the treatment)
    7 Tele- Yoga Therapy for Patients With Chronic Pain During Covid-19 Lockdown: A Prospective Non-randomized Single Arm Clinical Trial

    Chronic pain is highly prevalent and associated with a large symptom burden, that is had been more concerning during Covid-19 outbreak and lockdown. Benefits of yoga in chronic pain management are very well known. With this background we developed Tele-Yoga therapy program and evaluated the success of this single arm study.

    NCT04457388
    Conditions
    1. Chronic Pain
    Interventions
    1. Other: Tele-Yoga Therapy
    MeSH:Chronic Pain
    HPO:Chronic pain

    Primary Outcomes

    Description: visual-analogic scale (VAS), using pain level from "no pain" (0) to "worst imaginable pain" (10)

    Measure: Pain Intensity

    Time: From baseline to 6-week post intervention

    Secondary Outcomes

    Description: Pain Disability Index (PDI) using seven rating scales, structured in Likert form, from "no disability" (0) to "worst disability" (10)

    Measure: Pain Disability

    Time: From baseline to 6-week post intervention

    Description: Hospital Anxiety Depression Scale, consisting of 7 scales for measuring anxiety levels

    Measure: Anxiety

    Time: From Baseline to 6-week post intervention

    Description: Hospital Anxiety Depression Scale, consisting of 7 scales for measuring depression levels

    Measure: Depression

    Time: From baseline to 6-week post intervention
    8 Virtual Pain Care for High Risk Veterans on Opioids During COVID19 (and Beyond)

    The COVID-19 pandemic is exacerbating the challenges faced by Veterans at risk of opioid overdose including Veterans prescribed moderate-to-high dose long-term opioid therapy (LTOT) whose usual treatment resources and coping strategies may be inaccessible. This project combines established VA care components to deploy and evaluate virtual models of care for Veterans on high-risk LTOT to meet the dual challenges of maintaining social distancing and delivery high quality care.

    NCT04539821
    Conditions
    1. Chronic Pain
    Interventions
    1. Other: VCPM
    MeSH:Chronic Pain
    HPO:Chronic pain

    Primary Outcomes

    Description: Although the project will use shared decision-making with Veterans, the percent of patients who agree to transfer will provide a realistic indicator of overall feasibility/acceptability.

    Measure: the percent of patients who agree to Buprenorphine transfer

    Time: 30 days

    Secondary Outcomes

    Description: overall measure of engagement

    Measure: percent of complete tapering or BUP transition

    Time: 60 days
    9 An Online Randomized Controlled Trial Comparing the Effects of Mindfulness, Sham Mindfulness and Book Listening Control on Pain Experience in Adults With Recurrent and Chronic Pain

    Both mindfulness meditation and expectancy effects are known to reduce pain intensity, pain unpleasantness and pain catastrophizing, but it is unknown whether and how expectancy effects contribute to the overall effect of mindfulness meditation on these outcomes, especially during significant global events such as the coronavirus pandemic. This study includes four interrelated aims that will probe these effects and interactions.

    NCT04602286
    Conditions
    1. Pain, Intractable
    2. Pain, Chronic
    Interventions
    1. Other: Meditation (1 x 20-minute guided audio training)
    MeSH:Chronic Pain Pain, Intractable
    HPO:Chronic pain

    Primary Outcomes

    Description: Assessed via a numerical rating scale (0=no pain, 10=most intense pain imaginable)

    Measure: Pain intensity

    Time: 40 minutes

    Description: assessed via a numerical rating scale (0=no pain, 10=most unpleasant pain imaginable)

    Measure: Pain Unpleasantness

    Time: 40 minutes

    Secondary Outcomes

    Description: assessed via the Pain Catastrophizing Scale (PCS; 0=no catastrophizing, 52=highest catastrophizing, 30+=clinically significant catastrophizing)

    Measure: Pain Catastrophizing

    Time: 40 minutes

    Other Outcomes

    Description: assessed via self-report questions (0=lowest expectancy, 10=highest expectancy)

    Measure: Expectancy

    Time: 40 minutes

    Description: assessed via the Pain-related Cognitive Processes Questionnaire (PCPQ-R; 0=lowest reappraisal, 4=highest reappraisal)

    Measure: Pain Reappraisal

    Time: 40 minutes

    Description: assessed via the Five Facet Mindfulness Questionnaire Observing Subscale (FFMQ-O; 1=lowest observing, 5=highest observing)

    Measure: Mindful observing

    Time: 40 minutes

    Description: assessed via the Five Facet Mindfulness Questionnaire Non-reacting Subscale (FFMQ-NR; 1=lowest non-reactivity, 5=highest non-reactivity)

    Measure: Mindful non-reactivity

    Time: 40 minutes

    Description: assessed via the State Mindfulness Survey (SMS; 1=lowest mindfulness, 21=highest mindfulness)

    Measure: State Mindfulness

    Time: 40 minutes

    Description: assessed via the Metacognitive Processes of Decentering - State (MpoD-s; 0=lowest decentering, 3=highest decentering)

    Measure: State Decentering

    Time: 40 minutes

    HPO Nodes


    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials

    Reports

    Data processed on January 01, 2021.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook